We cordially invite you to participate in an open-label, multicenter clinical trial aimed at evaluating the safety and pharmacokinetics, as well as determining the maximum tolerated and therapeutic doses, of two kinase inhibitors—trametinib and gilteritinib—in combination with dexamethasone in adult cancer patients.